Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Welcome Email

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, GLP-1RA, Other, Topics

New Ph3b Survodutide Studies; Regeneron Ph3 Olatorepatide Obesity Program; Corsera Ph1 Angiotensinogen + PCSK9 Combo Study

Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: Boehringer Ingelheim has registered three new Ph3b survodutide studies (SYNCHRONIZE-HERA; SYNCHRONIZE-START; ELEVATE-LIVER); Regeneron posted its Ph3 olatorepatide obesity program on EudraCT (RISE-1; RISE-2); and Corsera initiated a Ph1 FIH study evaluating its angiotensinogen siRNA alone and in combination with a PCSK9 siRNA (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.